HRE-based gene therapy (Aventis)

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug NameHRE-based gene therapy (Aventis)
Drug Alias NameLentiVector-based gene therapy (Aventis)hypoxia response element gene therapy (Aventis)retroviral gene therapy (Aventis)
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Retroviral vector
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsCoronary Artery DiseasePeripheral arterial occlusive disorders
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryFrance
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesAventis
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAventis
Active IndicationsN/A
Inactive IndicationsCoronary Artery DiseasePeripheral arterial occlusive disorders

Other Information

ATC CodeN/A
Related LinksN/A